Mir-326 for the treatment of cancer
AssigneeFundacióN Para La InvestigacióN BioméDica Del Hospital Universitario RamóN Y Cajal
InventorsElisa CONDE MORENO, Maria Laura GARCÍA BERMEJO, Silvia SERRANO HUERTAS, Lorena CRESPO TORO, Miren Edurne RAMOS MUÑOZ, Eulalia RODRÍGUEZ MARTÍN
Life of this patent
Estimating the term…
Abstract
The present invention discloses a method of therapeutically treating cancer, in particular CRC (colorectal cancer), or of reducing the risk of cancer in particular CRC, disease progression in a patient comprising expressing miR-326 in the epithelial tumor cells and immune cells of said patient, preferably in NK and macrophages, and suitable means for said methods.
Claims21
A method for treatment of cancer in a subject in need thereof, comprising administering to the subject a composition comprising macrophages and/or natural killer (NK) cells, wherein these cells have been generated or obtained by transforming, transducing or transfecting these cells with miR-326, the seed sequence of miR-326 or a precursor of miR-326, or with a delivery vehicle comprising a sequence coding for miR-326, the seed sequence of miR-326 or a precursor of miR-326, wherein the transformation, transduction or transfection is capable of significantly increasing the intracellular expression of miR-326, the seed sequence of miR-326 or a precursor of miR-326, transiently or permanently, in comparison to an untreated control macrophage or NK, and optionally, with the proviso that the composition comprises macrophages, simultaneously or subsequently to the transformation, transduction or transfection culturing these cells in the presence of a pro-inflammatory medium.
A composition comprising macrophages and/or natural killer (NK) cells, wherein these cells have been generated or obtained by transforming, transducing or transfecting these cells with miR-326, the seed sequence of miR-326 or a precursor of miR-326, or with a delivery vehicle comprising a sequence coding for miR-326, the seed sequence of miR-326 or a precursor of miR-326, wherein the transformation, transduction or transfection is capable of significantly increasing the intracellular expression of miR-326, the seed sequence of miR-326 or a precursor of miR-326, transiently or permanently, in comparison to an untreated control macrophage or NK, and optionally, with the proviso that the composition comprises macrophages, simultaneously or subsequently to the transformation, transduction or transfection culturing these cells in the presence of a pro-inflammatory medium.
(canceled)
A method for treatment of cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a miR-326, the seed sequence of miR-326 or a precursor of miR-326, or a delivery delivery vehicle comprising miR-326, the seed sequence of miR-326 or a precursor of miR-326, or a delivery vehicle comprising a sequence coding for miR-326, the seed sequence of miR-326 or a precursor of miR-326, wherein said composition is capable of significantly increasing the intracellular concentration of miR-326, the seed sequence of miR-326 or a precursor of miR-326 in the macrophages or natural killer (NK) cells of a subject in need thereof in comparison to an untreated control macrophage or NK.
Dependencies are inferred from the claim text.